BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 31401373)

  • 1. Searching new structural scaffolds for BRAF inhibitors. An integrative study using theoretical and experimental techniques.
    Campos LE; Garibotto FM; Angelina E; Kos J; Tomašič T; Zidar N; Kikelj D; Gonec T; Marvanova P; Mokry P; Jampilek J; Alvarez SE; Enriz RD
    Bioorg Chem; 2019 Oct; 91():103125. PubMed ID: 31401373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydroxynaphthalenecarboxamides and substituted piperazinylpropandiols, two new series of BRAF inhibitors. A theoretical and experimental study.
    Campos LE; Garibotto F; Angelina E; Kos J; Gonec T; Marvanova P; Vettorazzi M; Oravec M; Jendrzejewska I; Jampilek J; Alvarez SE; Enriz RD
    Bioorg Chem; 2020 Oct; 103():104145. PubMed ID: 32801082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docking-based structural splicing and reassembly strategy to develop novel deazapurine derivatives as potent B-Raf
    Wang GM; Wang X; Zhu JM; Guo BB; Yang Z; Xu ZJ; Li B; Wang HY; Meng LH; Zhu WL; Ding J
    Acta Pharmacol Sin; 2017 Jul; 38(7):1059-1068. PubMed ID: 28414204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural optimization of imidazothiazole derivatives affords a new promising series as B-Raf V600E inhibitors; synthesis, in vitro assay and in silico screening.
    Ammar UM; Abdel-Maksoud MS; Ali EMH; Mersal KI; Ho Yoo K; Oh CH
    Bioorg Chem; 2020 Jul; 100():103967. PubMed ID: 32470760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and biological evaluation of novel imidazole derivatives possessing terminal sulphonamides as potential BRAF
    Ali EMH; Abdel-Maksoud MS; Ammar UM; Mersal KI; Ho Yoo K; Jooryeong P; Oh CH
    Bioorg Chem; 2021 Jan; 106():104508. PubMed ID: 33280830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, biological evaluation, and docking studies of novel (imidazol-5-yl)pyrimidine-based derivatives as dual BRAF
    Ali EMH; El-Telbany RFA; Abdel-Maksoud MS; Ammar UM; Mersal KI; Zaraei SO; El-Gamal MI; Choi SI; Lee KT; Kim HK; Lee KH; Oh CH
    Eur J Med Chem; 2021 Apr; 215():113277. PubMed ID: 33601311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modification of imidazothiazole derivatives gives promising activity in B-Raf kinase enzyme inhibition; synthesis, in vitro studies and molecular docking.
    Ammar UM; Abdel-Maksoud MS; Mersal KI; Ali EMH; Yoo KH; Choi HS; Lee JK; Cha SY; Oh CH
    Bioorg Med Chem Lett; 2020 Oct; 30(20):127478. PubMed ID: 32781217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and biological evaluation of novel triaryl pyrazoline derivatives with dioxane moiety for selective BRAF
    Li HL; Su MM; Xu YJ; Xu C; Yang YS; Zhu HL
    Eur J Med Chem; 2018 Jul; 155():725-735. PubMed ID: 29940463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
    Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
    Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An integrative study to identify novel scaffolds for sphingosine kinase 1 inhibitors.
    Vettorazzi M; Angelina E; Lima S; Gonec T; Otevrel J; Marvanova P; Padrtova T; Mokry P; Bobal P; Acosta LM; Palma A; Cobo J; Bobalova J; Csollei J; Malik I; Alvarez S; Spiegel S; Jampilek J; Enriz RD
    Eur J Med Chem; 2017 Oct; 139():461-481. PubMed ID: 28822281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticancer profile of newly synthesized BRAF inhibitors possess 5-(pyrimidin-4-yl)imidazo[2,1-b]thiazole scaffold.
    Abdel-Maksoud MS; Ammar UM; Oh CH
    Bioorg Med Chem; 2019 May; 27(10):2041-2051. PubMed ID: 30955995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
    Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
    Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insight into molecular dynamics simulation of BRAF(V600E) and potent novel inhibitors for malignant melanoma.
    Tang HC; Chen YC
    Int J Nanomedicine; 2015; 10():3131-46. PubMed ID: 25960652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and biological evaluation of novel 5-phenyl-1H-pyrazole derivatives as potential BRAF(V600E) inhibitors.
    Wang SF; Zhu YL; Zhu PT; Makawana JA; Zhang YL; Zhao MY; Lv PC; Zhu HL
    Bioorg Med Chem; 2014 Nov; 22(21):6201-8. PubMed ID: 25267006
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S
    Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463
    [No Abstract]   [Full Text] [Related]  

  • 16. Identification of type II inhibitors targeting BRAF using privileged pharmacophores.
    Zhang Q; Wang J; Wang F; Chen X; He Y; You Q; Zhou H
    Chem Biol Drug Des; 2014 Jan; 83(1):27-36. PubMed ID: 24164966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and biological evaluation of pyrazole derivatives containing acetamide bond as potential BRAF
    Wang CR; Wang ZF; Shi L; Wang ZC; Zhu HL
    Bioorg Med Chem Lett; 2018 Aug; 28(14):2382-2390. PubMed ID: 29934244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.
    Dankner M; Lajoie M; Moldoveanu D; Nguyen TT; Savage P; Rajkumar S; Huang X; Lvova M; Protopopov A; Vuzman D; Hogg D; Park M; Guiot MC; Petrecca K; Mihalcioiu C; Watson IR; Siegel PM; Rose AAN
    Clin Cancer Res; 2018 Dec; 24(24):6483-6494. PubMed ID: 29903896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NO-releasing STAT3 inhibitors suppress BRAF-mutant melanoma growth.
    Kaoud TS; Mohassab AM; Hassan HA; Yan C; Van Ravenstein SX; Abdelhamid D; Dalby KN; Abdel-Aziz M
    Eur J Med Chem; 2020 Jan; 186():111885. PubMed ID: 31784187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.